Results 231 to 240 of about 7,636,605 (392)

Drug industry loses bid to block disclosure of doctors' gifts [PDF]

, 2007
Bob Burton
openalex   +1 more source

NR4A1 Exerts Pro‐Tumor Role in Glioblastoma via Inducing xCT/GPX4‐Regulated Ferroptosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose This study investigates NR4A1's paradoxical roles in glioblastoma (GBM) progression, focusing on its mechanistic link to ferroptosis regulation. We aimed to resolve conflicting reports of NR4A1 as both an oncogene and a tumor suppressor by defining its transcriptional control over xCT/GPX4‐mediated iron homeostasis and its clinical ...
Peng Tao, Shikuan Din, Zhengkang Fu, Qian Sun, Xiwei Zhu, Yuxin Wei, Huan Qu, Xinyi Zhang, Jiaxuan Liu, Chuhua Fu, Qianxue Chen   +10 more
wiley   +1 more source

Evolution of traditional Chinese medicine registration review and approval policies: research based on the LDA topic model. [PDF]

Front Public Health
Lu K, Xie M, Sun W, Liu Y.
europepmc   +1 more source

Industry & the FDA in Pediatric Oncology Drug Development

, 2003
Gregory H. Reaman
openalex   +1 more source

A European-Inspired Renaissance for China's Drug Industry? [PDF]

, 2007
Hao Xin
openalex   +1 more source

Longitudinal Study of Salivary Biomarkers in the Definition of Clinico‐Molecular Progression of Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
Longitudinal changes in salivary biomarkers in Parkinson’s disease (PD) from early (T0) to 4‐year follow‐up (T1), quantified by ELISA: oligomeric and total α‐synuclein, total and phosphorylated tau, MAP1LC3B (autophagy), and TNFa (inflammation). Blue arrows indicate direction of change at T1 vs T0 (up = increase; down = decrease).
Maria Ilenia De Bartolo, Daniele Belvisi, Matteo Costanzo, Claudia Caturano, Francesco Emanuele Bellomi, Carolina Cutrona, Flavia Aiello, Giorgio Leodori, Massimo Marano, Romina Mancinelli, Antonella Conte, Giovanni Fabbrini, Alfredo Berardelli, Giorgio Vivacqua   +13 more
wiley   +1 more source

Correction: A new selective culture medium for isolation of <i>Burkholderia cepacia</i> complex in pharmaceutical industry. [PDF]

Front Microbiol
Yu M, Wang S, Zhong Y, Yuan L, An L, Feng D, Liu Z, Ma S.   +7 more
europepmc   +1 more source

Drug Industry In Peril [PDF]

Health Affairs, 2017
openaire   +2 more sources

CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the
Yasuaki Mizutani, Tsuyoshi Nakai, Yasuhiro Maeda, Reiko Ohdake, Atsuhiro Higashi, Toshiki Maeda, Ryunosuke Nagao, Sayuri Shima, Kazuya Kawabata, Akihiro Ueda, Mizuki Ito, Hirohisa Watanabe   +11 more
wiley   +1 more source

Impact of equivalent units of production on state-controlled unit cost calculation for fair pricing of pharmaceuticals: a scoping review. [PDF]

J Pharm Policy Pract
Udoh S, Wnuk-Pel T.
europepmc   +1 more source